Allist holds approximately 300 million yuan in equity of its overseas partner at mid-year.

Recently, ArriVent announced that the global Phase III FURVENT trial of furmonertinib, developed in collaboration with Allist, did not meet its primary endpoint. The trial targeted first-line treatment for EGFR exon 20 insertion mutation-positive locally advanced or metastatic non-squamous non-small cell lung cancer. According to Tianyancha, Shanghai Allist Pharmaceuticals Co., Ltd.'s 2026 semi-annual report disclosed that as of June 30, the book value of the company's equity stake in ArriVent was approximately 302 million yuan, up 67.31% from the end of the previous year, with the report attributing the increase to a rise in ArriVent's stock price. The two parties have another drug collaboration: in August of this year, Allist obtained from ArriVent an exclusive license for the research and development, manufacturing, registration, and commercialization of the ADC drug AST12608 in China.